Compare Gilead Sciences, Inc. (GILD) vs JetBlue Airways Corporation (JBLU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs JetBlue Airways Corporation — how do they compare? Gilead Sciences, Inc. trades at $136.16 (market cap $163.51B), while JetBlue Airways Corporation trades at $5.6 (market cap $2.07B). The key difference: Gilead Sciences, Inc. is far larger — about 79× JetBlue Airways Corporation's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while JetBlue Airways Corporation pays none. Which is the better fit depends on your goals.
| GILD | JBLU | |
|---|---|---|
Market Cap | $163.51B | $2.07B |
Sector | Health | Industrials |
52-Week High | $155.80 | $6.46 |
52-Week Low | $108.22 | $4.03 |
Enterprise Value | $178.05B | $9.24B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
JetBlue (JBLU) trades at $5.525, up 3.66% today, but remains below the consensus price target of $5.12. The stock shows a neutral technical signal with mixed moving averages and oscillators. Fundamentally, JBLU faces challenges with negative net income margins and ROE, though it maintains a low P/S ratio of 0.22. Recent news highlights expansion at Fort Lauderdale and a new payment partnership, but earnings misses in Q4 2025 and Q1 2026 underscore ongoing profitability struggles amid high debt levels.
The outlook for JBLU is cautious due to persistent losses and elevated leverage, offset by cost initiatives and strategic growth. Risks include fuel price volatility and competitive pressures, while analyst sentiment is mixed with a majority hold rating. Investors should weigh turnaround potential against financial headwinds in a cyclical industry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →
